


SmithKline Beecham (Mauritius) Limited
(Registered Number 295756)

Annual Report and Financial Statements

For the year ended 31st December 2005

Registered office address:
980 Great West Road
Brentford
Middlesex
TW8 9GS



SmithKline Beecham (Mauritius) Limited
Annual Report and Financial Statements
For the year ended 31st December 2005

| | Pages |
|--|--------------|
| Directors' Report | 1-2 |
| Independent Auditors' Report | 3 |
| Profit and Loss Account | 4 |
| Statement of Total Recognised Gains and Losses | 5 |
| Balance Sheet | 6 |
| Notes to the Financial Statements | 7-9 |

SmithKline Beecham (Mauritius) Limited

Directors' Report for the year ended 31st December 2005

The Directors submit their report and the audited financial statements for the year ended 31st December 2005.

Principal activities

The principal activity of the Company is the sale of pharmaceutical and consumer healthcare products through its branch in Madagascar, which ceased trading during 2004.

Review of business

The Company made a loss on ordinary activities after taxation of £9,000 (2004 - loss of £2,000). The Directors are of the opinion that the current level of activity will continue in the foreseeable future.

The loss for the financial year of £9,000 will be transferred from reserves (2004 - loss for the financial year of £2,000 transferred from reserves).

Results and dividends

The Company's results for the financial year are shown in the profit and loss account on page 4.

The Directors propose that no dividend be paid to the holders of Ordinary Shares in respect of the year ended 31st December 2005 (2004 - £nil).

Directors and their interests

The Directors of the Company who served during the year are as follows:

Edinburgh Pharmaceutical Industries Limited
Glaxo Group Limited

No Director had, during the year or at the end of the year, any material interest in any contract of significance to the Company's business except where such an interest may arise in the ordinary course of business.

Save as disclosed, no arrangements to which the Company was a party existed at the end of the year, or at any time during the year, which would enable the Directors to acquire benefits through the acquisition of shares, or debentures of the Company, or any body corporate within GlaxoSmithKline Group (the Group).

At 31st December 2005 none of the Directors had beneficial interests in the shares of any other Group company, except where such a beneficial interest may arise in the ordinary course of business.

Directors' indemnity

Each of the Directors benefits from an indemnity given by the Company under its articles of association. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of its duties.

SmithKline Beecham (Mauritius) Limited

Directors' Report for the year ended 31st December 2005

Statement of Directors' responsibilities

Company law requires the Directors to prepare financial statements for each financial year that give a true and fair view of the state of affairs of the Company and of the profit or loss for that year.

In preparing the financial statements the Directors are required to:

- Select suitable accounting policies and then apply them consistently.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.


The Directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the accounts.

Auditors

Elective resolutions to dispense with holding Annual General Meetings, the laying of accounts before the Company in general meetings and the appointment of Auditors annually are currently in force. The Auditors, PricewaterhouseCoopers LLP, will therefore be deemed to have been re-appointed at the end of the period of 28 days beginning with the day on which copies of this Report and Accounts are sent to members unless a resolution is passed under Section 393 of the Companies Act to the effect that their re-appointment be brought to an end.

By order of the Board



P Williamson

For and on behalf of Edinburgh Pharmaceutical Industries Limited - Secretary

23rd February 2006

SmithKline Beecham (Mauritius) Limited

Independent auditors' report to the shareholders of SmithKline Beecham (Mauritius) Limited

We have audited the financial statements of SmithKline Beecham (Mauritius) Limited for the year ended 31st December 2005 which comprise the Profit and Loss Account, the Statement of Total Recognised Gains and Losses, the Balance Sheet, and the related notes. These financial statements have been prepared under the accounting policies set out therein.

Respective responsibilities of directors and auditors

As described in the Statement of Directors' Responsibilities the Company's directors are responsible for the preparation of the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland). This report, including the opinion, has been prepared for and only for the Company's members as a body in accordance with Section 235 of the Companies Act 1985 and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the Directors' Report is not consistent with the financial statements, if the Company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and other transactions is not disclosed.

We read the Directors' Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgments made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the Company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion the financial statements:

- give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the Company's affairs as at 31st December and of its loss for the year then ended; and
- have been properly prepared in accordance with the Companies Act 1985.

PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
Chartered Accountants and Registered Auditors
London
23rd February 2006

SmithKline Beecham (Mauritius) Limited

Profit and Loss Account

For the year ended 31st December 2005

| | Notes | 2005 £000 | 2004 £000 |
|---|-------|--------------|--------------|
| Turnover | | - | - |
| Cost of sales | | - | - |
| Gross profit | | - | - |
| Administrative expenses | | (6) | (4) |
| Operating loss | 2 | (6) | (4) |
| Net interest receivable | 3 | 3 | 2 |
| Loss on ordinary activities before taxation | | (3) | (2) |
| Taxation | 4 | (6) | - |
| Loss on ordinary activities after taxation | | (9) | (2) |
| Loss for the financial year | 8 | (9) | (2) |

The results disclosed above relate entirely to discontinued operations.

There is no difference between the loss on ordinary activities before taxation and the loss for the financial year stated above and their historical cost equivalents.

The notes on pages 7 to 9 form part of these financial statements.

SmithKline Beecham (Mauritius) Limited

**Statement of Total Recognised Gains and Losses
For the year ended 31st December 2005**

| | 2005 | 2004 |
|---|-------------|--------------|
| | £000 | £000 |
| Loss for the financial year | (9) | (2) |
| Exchange movement on overseas net assets | (59) | (405) |
| Total gains and losses recognised | (68) | (407) |

The notes on pages 7 to 9 form part of these financial statements.


SmithKline Beecham (Mauritius) Limited

Balance Sheet

As at 31st December 2005

| | | 2005 | 2004 |
|---|-------|--------------|--------------|
| | Notes | £000 | £000 |
| Debtors | 5 | 1,687 | 1,658 |
| Cash at bank | | 93 | 148 |
| Current assets | | 1,780 | 1,806 |
| Creditors: amounts due within one year | 6 | (292) | (250) |
| Net current assets | | 1,488 | 1,556 |
| Total assets less current liabilities | | 1,488 | 1,556 |
| Net assets | | 1,488 | 1,556 |
| Capital and reserves | | | |
| Called up share capital | 7 | 536 | 536 |
| Share premium account | 8 | 2 | 2 |
| Profit and loss account | 8 | 950 | 1,018 |
| Equity shareholders' funds | 9 | 1,488 | 1,556 |

The accounts on pages 4 to 9 were approved by the Board of Directors on 23rd February 2006 and were signed on its behalf by:



P Blackburn

For and on behalf of Glaxo Group Limited – Director

The notes on pages 7 to 9 form part of these financial statements.

SmithKline Beecham (Mauritius) Limited

Notes to the Financial Statements for the year ended 31st December 2005

1 Accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below.

(a) Basis of accounting

These financial statements have been prepared using the historical cost convention, and have been drawn up in accordance with UK generally accepted accounting principles and with UK accounting presentation.

(b) Foreign currency transactions

Foreign currency transactions are booked in local currency at the exchange rate ruling on the date of the transaction, or at the forward rate if hedged by a forward exchange contract. Foreign currency assets and liabilities are translated into local currency at rates of exchange ruling at the balance sheet date, or at the forward rate. Exchange differences are included in trading profit. The retranslation of the opening reserves and results for the period of overseas branches that are denominated in a foreign currency are taken to the statement of total recognised gains and losses.

(c) Taxation

The Company accounts for taxation which is deferred or accelerated by reason of timing differences which have originated but not reversed by the balance sheet date. Deferred tax assets are only recognised to the extent that they are considered recoverable against future taxable profits.

Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the timing differences are expected to reverse. Deferred tax liabilities and assets are not discounted.

2 Operating profit

The auditors' remuneration has been borne by the Group.

GlaxoSmithKline Services Unlimited provides various services and facilities to the Company including selling, finance and administrative services for which a management fee is charged.

3 Net interest receivable

| | 2005 £000 | 2004 £000 |
|----------------------------------|--------------|--------------|
| Investment income | | |
| On loans with Group undertakings | 3 | 2 |
| | 3 | 2 |

SmithKline Beecham (Mauritius) Limited

Notes to the Financial Statements for the year ended 31st December 2005

4 Taxation

| | 2005 £000 | 2004 £000 |
|---|--------------|--------------|
| Taxation charge / (credit) based on profits for the period | | |
| UK corporation tax at 30% (2004 - 30%) | (1) | (1) |
| Under provision in previous years | 7 | 1 |
| | 6 | - |

There are no items required to reconcile the profit before taxation at the statutory rate of 30% to the current taxation charge other than the prior year adjustment shown above.

5 Debtors

| | 2005 £000 | 2004 £000 |
|------------------------------------|--------------|--------------|
| Amounts due within one year | | |
| Amounts owed by Group undertakings | 1,631 | 1,602 |
| Taxation | 56 | 56 |
| | 1,687 | 1,658 |

6 Creditors

| | 2005 £000 | 2004 £000 |
|------------------------------------|--------------|--------------|
| Amounts due within one year | | |
| Amounts owed to Group undertakings | 266 | 233 |
| Overseas taxation | 26 | 17 |
| | 292 | 250 |

7 Called up share capital - equity interests

| | 2005 Number of shares | 2004 Number of shares | 2005 £000 | 2004 £000 |
|------------------------------|-----------------------------|-----------------------------|--------------|--------------|
| Authorised | | | | |
| Ordinary Shares of £1 each | 612,001 | 612,001 | 612 | 612 |
| Issued and fully paid | | | | |
| Ordinary Shares of £1 each | 535,927 | 535,927 | 536 | 536 |

SmithKline Beecham (Mauritius) Limited

Notes to the Financial Statements for the year ended 31st December 2005

8 Reserves - equity interests

| | Profit & Loss account £000 | Share Premium £000 | Total Reserves £000 |
|-----------------------------|----------------------------------|--------------------------|---------------------------|
| At 1st January 2005 | 1,018 | 2 | 1,020 |
| Loss for the financial year | (9) | - | (9) |
| Exchange movements | (59) | - | (59) |
| At 31st December 2005 | 950 | 2 | 952 |

9 Reconciliation of movements in shareholders' funds

| | 2005 £000 | 2004 £000 |
|--|--------------|--------------|
| Loss for the financial year | (9) | (2) |
| Exchange movements | (59) | (405) |
| Net addition to shareholders' funds | (68) | (407) |
| Opening shareholders' funds | 1,556 | 1,963 |
| Closing shareholders' funds – equity interests | 1,488 | 1,556 |

10 Cash flow statement

A cash flow statement has been included in the consolidated financial statements of GlaxoSmithKline plc, the ultimate parent undertaking. As a wholly owned subsidiary of the ultimate parent undertaking, advantage has been taken of the exemption afforded by FRS 1 'Cash Flow Statements' (Revised 1996) not to prepare a cash flow statement.

11 Ultimate parent undertaking

GlaxoSmithKline plc, registered in England and Wales, is the Company's ultimate parent undertaking. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company, are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated accounts can be obtained from The Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex TW8 9GS. The immediate parent undertaking is SmithKline Beecham plc.

12 Related party transactions

As a wholly owned subsidiary of the ultimate parent company, GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 8 'Related Party Disclosures' not to disclose any related party transactions within the Group. There are no other related party transactions.